
Perrigo Company plc
PRGOHealthcare|Drug Manufacturers - Specialty & Generic|IE
$15.85
+0.14 (+0.89%)
DCF Value
$78.08
Cash / Share
$3.13
Clinical Trials (10)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT01257542 Acute Cough Study In Children | Common Cold, Infections, Upper Respiratory Tract | P4 | Terminated | 140 | RCT, Double-blind | Dextromethorphan, Placebo |
| NCT01744106 A Multicenter Study of Pseudoephedrine for the Temporary Relief of Nasal Congestion in Children With the Common Cold | Nasal Congestion Associated With the Common Cold | P3 | Completed | 565 | RCT, Double-blind | pseudoephedrine hydrochloride 30 mg tablets, Placebo tablets |
| NCT03518268 Vivomixx for Prevention of Bone Loss in Women With Breast Cancer Treated With an Aromatase Inhibitor | Breast Cancer, Osteoporosis, Osteopenia | P1P2 | Unknown | 40 | RCT, Double-blind | Vivomixx, Placebo |
| NCT00804440 Bioequivalence Study Between Two Oral Formulations of Ibuprofen 800 mg Tablets Under Fasting Conditions | Bioequivalency | P1 | Completed | 30 | RCT, Open-label | Ibuprofen Tablets, 800 mg |
| NCT00803764 Bioequivalence Study Between Two Oral Formulations of Naproxen 500 mg Tablets Under Fed Conditions | Bioequivalency | P1 | Completed | 34 | RCT, Open-label | Naproxen Tablets, 500 mg |
| NCT00803192 Bioequivalence Study Between Two Oral Formulations of Famotidine Tablets Under Fed Conditions | Bioavailability | P1 | Completed | 44 | RCT, Open-label | Famotidine Tablets, 40 mg |
| NCT00804401 Bioequivalence Study Between Two Oral Formulations of Naproxen 500 mg Tablets Under Fasting Conditions | Bioequivalency | P1 | Completed | 34 | RCT, Open-label | Naproxen Tablets, 500 mg |
| NCT00803946 Bioequivalence Study Between Two Oral Formulations of Ibuprofen 800 mg Tablets Under Fed Conditions | Bioequivalency | P1 | Completed | 30 | RCT, Open-label | Ibuprofen Tablets, 800 mg |
| NCT00802828 Bioequivalence Study Between Two Oral Formulations of Famotidine Tablets Under Fasting Conditions | Bioavailability | P1 | Completed | 44 | RCT, Open-label | Famotidine Tablets, 40 mg |
| NCT04801134 Interventions to Manage Food Insecurity and Inappropriate Feeding Practices Related to the COVID-19 Pandemic | Food Insecurity, Children, Only | N/A | Unknown | 50 | Open-label | — |